10835 Road To The Cure, Suite 100, San Diego, CA 92121, Phone: (858) 362-6295
<h2>State of the Art Technology</h2><p>We work with much stacked in our favor: exceptional talent working on promising technology in a proven field with committed investors. To conduct our work, we have onsite access to state-of-the-art equipment, including multiple Biacore® and KinExA® systems that are widely used by industry to generate high quality data on key characteristics of antibodies including their kinetics, affinity and specificity. Defining interaction characteristics using these systems helps AnaptysBio select the best therapeutic candidates as early as possible. Shown here is a Biacore® A100 purchased by AnaptysBio in 2008.</p> <h2>Our People</h2><p>Our success depends on our current and future employees – their commitment to the job, ability to solve problems, deal with setbacks and capitalize on opportunities, and our ability to respect each other and work as a team. How we work together as a team, and execute our plans, will ultimately determine our success. With this in mind, it is our objective to provide you with an environment in which you will excel and cause others to do the same.</p> <h2>Modern Research Facilities in San Diego, California</h2><p>AnaptysBio is located in the La Jolla Torrey Pines bioscience hub with more than 200 biotech companies and leading research institutions within a 10 mile radius. Our street name – Road to the Cure – reflects the important task we embark upon daily of creating new medicines.</p> <h2>Focused on Therapeutic Antibodies</h2><p>Therapeutic antibodies are widely expected by industry analysts and research experts to remain the largest growing segment of pharmaceuticals for the foreseeable future. AnaptysBio is well positioned to independently, and through partnerships, contribute to this trend by creating a vast number of novel and improved antibody medicines using our SHM-based, next generation platform for antibody discovery and optimization.</p> <h2>Advancing SHM Technology</h2><p>Our SHM-Platform™ utilizes the key components of SHM, mammalian cell expression/display, and flow cytometry technology to enable the rapid variation and selection of antibodies with enhanced bioactivites. Shown here is one of our multi-parameter high-throughput sorting flow cytometers. AnaptysBio’s success has the potential to transform the lives of patients from a state of suffering to enjoying life in a way they never thought possible – again or for the first time.</p> <h2>Part of One of the Nation’s Leading Biotech Clusters</h2><p>AnaptysBio is located in the La Jolla Torrey Pines bioscience hub, surrounded by modern research facilities in the heart of one of the nation’s three largest biotech clusters, and near the beautiful San Diego coast line. Our employees enjoy a challenging, rewarding work environment and a sunny, temperate climate where you can enjoy a variety of outdoor activities year-round.</p> <h2>Accomplished Leadership</h2><p>Our management team is comprised of individuals with extensive experience and recognized accomplishments in the technical, scientific and business aspects of therapeutic antibodies. Our internal team works together with leading outside experts to ensure our ideas, strategies, issues and opportunities are well vetted and benefit from a diversity of experiences, perspectives and wisdom. (L: Dennis Burton, Ph.D., Prof. Dept. Immunology, The Scripps Research Institute; R: Chairman and CEO, Tom Smart)</p>

About AnaptysBio

Founded in 2005, AnaptysBio, Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization.  SHM is the body’s natural process for generating potent antibodies to fight disease.  The Company’s SHM-Platform™ utilizes the key components of SHM and other state-of-the-art techniques such as mammalian cell expression/display and flow cytometry to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies.  This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties.  The company has established broad intellectual property around the use of SHM for therapeutic antibody applications, and is currently building a pipeline of novel therapeutic antibody product candidates.